secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K/A
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001104659-26-044969
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio corrects Series G warrant expiration to May 20, 2026; clinical trial for IBIO-600 cleared in Australia
--------------------------------------------------------------------------------

- Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).
- Outstanding Series G warrants to purchase ~11.07M shares; 36.14M shares of common stock outstanding as of April 17, 2026.
- Received CTN acknowledgement from Australia's TGA and ethics approval for Phase 1 trial of IBIO-600; first dosing expected Q2 2026.
- Pre-funded warrants for 13.79M shares issued upon exercise of Series G warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/0001104659-26-044969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/ibio-20260408x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer